Please note that slides are for review only and not to be repurposed or published.

Interactive Tumor Panel: Clinical Investigators Discuss Available Research Shaping the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Lung Cancer

Introduction:
Dr Love

MODULE 1:
Available Research Data with and Practical Integration of Anti-PD-1/PD-L1 Antibodies into Current Treatment Algorithms for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Gandhi

MODULE 2:
Current Role of Immune Checkpoint Inhibitors in Combination with Chemotherapy and/or Anti-angiogenic Agents in the Treatment of Metastatic Disease — Dr Langer

MODULE 3:
Predictors of Response to Immune Checkpoint Inhibitors; Potential Role of Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies in Combination — Dr Hellmann

MODULE 4:
Role of Immune Checkpoint Inhibition in Patients with Actionable Tumor Mutations; Ongoing Evaluation of Combinations of Targeted Therapy and Immunotherapy — Dr Herbst

MODULE 5:
Other Potentially Targetable Immune Checkpoints in NSCLC; Future Directions for Clinical and Translational Research — Dr Borghaei

Live Poll Results
Download

Data + Perspectives: Biologic Basis and Available Clinical Research Underlying the Protocol and Nonresearch Use of PARP Inhibition in Patients with Ovarian and Breast Cancer

Introduction:
Dr Love

MODULE 1:
Current Clinical Role and Ongoing Evaluation of PARP Inhibition in the Management of Ovarian Cancer (OC) — Dr Matulonis

MODULE 2:
Assessment and Biologic Implications of BRCA Mutations or Other Genomic Signatures Predictive of Response to PARP Inhibition in OC — Dr Moore

MODULE 3:
Available Research Data with and Practical Integration of PARP Inhibition in Metastatic Breast Cancer (mBC) — Dr Robson

MODULE 4:
Prevalence of Germline and Somatic BRCA and BRCA-Like Mutations in BC; Current Testing Algorithms and Clinical Implications — Dr Tutt

Live Poll Results
Download